STOCK TITAN

[SCHEDULE 13G/A] PALISADE BIO, INC. Amended Passive Investment Disclosure

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
SCHEDULE 13G/A

Rhea-AI Filing Summary

Palisade Bio, Inc. received an updated ownership filing showing that investment entities affiliated with Point72 report a significant passive stake in the company. As of the close of business on December 31, 2025, Point72 Asset Management, L.P., Point72 Capital Advisors, Inc., and Steven A. Cohen collectively reported beneficial ownership of 10,495,252 shares of Palisade Bio common stock, representing 7.0% of the outstanding class. They report no sole voting or dispositive power, but shared voting and shared dispositive power over all these shares, which are held by Point72 Associates, LLC under an investment management agreement. The filing is made on a Schedule 13G/A basis, with the certifying party stating the securities were not acquired and are not held for the purpose of changing or influencing control of Palisade Bio.

Positive

  • None.

Negative

  • None.





Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)






SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G



Point72 Asset Management, L.P.
Signature:/s/ Jason M. Colombo
Name/Title:Jason M. Colombo, Authorized Person
Date:02/17/2026
Point72 Capital Advisors, Inc.
Signature:/s/ Jason M. Colombo
Name/Title:Jason M. Colombo, Authorized Person
Date:02/17/2026
Steven A. Cohen
Signature:/s/ Jason M. Colombo
Name/Title:Jason M. Colombo, Authorized Person
Date:02/17/2026
Palisade Bio Inc

NASDAQ:PALI

PALI Rankings

PALI Latest News

PALI Latest SEC Filings

PALI Stock Data

258.12M
6.13M
Biotechnology
Biological Products, (no Diagnostic Substances)
Link
United States
CARLSBAD